are bromantane and Noopept proven cognitive enhancers for healthy people?

updated

both compounds have human records. those records answer narrower questions than healthy cognitive enhancement marketing asks.

verdict: human evidence present, healthy-enhancement claim unproven (disease-specific data / transfer gap)

quick answer

bromantane has older human evidence in asthenic disorders and a ten-person acute healthy-volunteer experiment. Noopept has a small active-comparator study in vascular or post-traumatic cognitive impairment. Neither record establishes durable cognitive enhancement in healthy people.

the evidence

the clinical records are not imaginary. (supported)

Bromantane reduced asthenic symptoms in an older placebo comparison, while Noopept reported disease-specific cognitive improvement against an active comparator.

the population transfer is large. (gap)

A tiny acute healthy-volunteer bromantane experiment and a Noopept impairment study cannot establish durable enhancement in healthy people.

adverse effects and product content stay in the answer. (risk)

The Noopept study reported sleep disturbance, irritability, and blood-pressure increases. A targeted assay of 10 US cognitive supplements found 5.1 to 40.6 mg of omberacetam per labeled serving and some undeclared drug combinations; it did not represent every supplement.

bottom line

human administration is not the same thing as proof for the marketed population and outcome.

scores

  • human administration: 62 · both have published clinical exposure
  • healthy cognition: 14 · tiny or absent direct outcome evidence
  • product identity: 30 · a targeted assay of 10 US products found variable omberacetam amounts and some undeclared combinations
  • transfer gap: 82 · asthenia and brain injury are not healthy enhancement

sources

  1. Bromantane randomized neurasthenia study. 2009. PMID 19491814. Randomized blind placebo-controlled 28-day human study.
  2. Bromantane multicenter asthenia study. 2011. PMID 21322821. Large Russian multicenter clinical report in 728 patients.
  3. Bromantane healthy-volunteer psychophysiology study. PMID 10998997. Small acute placebo comparison in ten healthy volunteers.
  4. Neznamov GG, Teleshova ES. 2009. PMID 19234797. Noopept versus piracetam active-comparator study in vascular and post-traumatic cognitive impairment.
  5. Cohen PA et al. Neurology Clinical Practice. 2021. PMCID PMC8382366. Targeted chemical analysis of 10 included US cognitive-enhancement products selected from 12 purchased brands.

keep reading

claim checks

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.